Reply to: “correspondence about “Efficacy and safety of basiliximab”

Reply to: “correspondence about “Efficacy and safety of basiliximab”

Bibliographic Details
Main Authors:	Mohamed Hashim, Ayman Alsebaey, Amr Ragab, Hossam Eldeen Soliman, Imam Waked
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268122000217

Similar Items

Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study
by: Mohamed Hashim, et al.
Published: (2020-09-01)

High efficacy of low-dose albumin infusion in the prevention of paracentesis-induced circulatory dysfunction
by: Ayman Alsebaey, et al.
Published: (2020-04-01)

Paracentesis-induced circulatory dysfunction: are there albumin alternatives?
by: Ayman Alsebaey, et al.
Published: (2020-08-01)

The comparative efficacy and safety of basiliximab and antithymocyte globulin in deceased donor kidney transplantation: a multicenter cohort study
by: Su Yeon Hong, et al.
Published: (2023-01-01)

Optimizing use of basiliximab in liver transplantation
by: Carlo B Ramirez, et al.
Published: (2010-01-01)

Fatal anaphylactic reaction due to Basiliximab
by: Patricia Lovisolo, et al.
Published: (2017-04-01)

Correspondence and reply
by: Boitumelo Semete-Makokotlela, et al.
Published: (2023-04-01)

The role of basiliximab in renal function after liver transplantation
by: Mikel Gastaca, MD
Published: (2022-03-01)

The role of basiliximab in the evolving renal transplantation immunosuppression protocol
by: Paola Salis, et al.
Published: (2008-06-01)

Reply to correspondence of Dr. Dimitri Poddighe
by: Tzu-I. Yang, et al.
Published: (2020-02-01)

Safety and efficacy of statins - Authors' reply
by: Collins, R, et al.
Published: (2017)

High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C
by: Mai Abozeid, et al.
Published: (2018-10-01)

Reduced Progression of Cardiac Allograft Vasculopathy with Routine Use of Induction Therapy with Basiliximab
by: Ricardo Wang, et al.
Published: (2015-01-01)

Prediction of minimal encephalopathy in patients with HCV-related cirrhosis using albumin-bilirubin, platelets-albumin-bilirubin score, albumin-bilirubin-platelets grade and ammonia level
by: Ayman Alsebaey
Published: (2020-04-01)

Correspondence: Reply to ‘Phantom phonon localization in relaxors’
by: Michael E. Manley, et al.
Published: (2017-12-01)

Efficacy and safety of cholesterol-lowering treatment - Reply
by: Baigent, C, et al.
Published: (2006)

Efficacy and safety of cholesterol-lowering treatment - Reply
by: Baigent, C, et al.
Published: (2006)

Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience
by: Masashi Furukawa, et al.
Published: (2022-06-01)

Comparative Study of the Cellular Pharmacodynamics of Tacrolimus in Renal Transplant Recipients Treated with and without Basiliximab
by: Kentaro Sugiyama Ph.D., et al.
Published: (2012-03-01)

Correspondence: Reply to: ‘Correspondence: Variations in ocean heat uptake during the surface warming hiatus’
by: Wei Liu, et al.
Published: (2016-08-01)

Correspondence: Reply to ‘On the bonding in ligand-protected gold clusters’
by: Wen Wu Xu, et al.
Published: (2017-11-01)

Correspondence: Reply to ‘DNA shape is insufficient to explain binding’
by: Sivakanthan Kasinathan, et al.
Published: (2017-06-01)

Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin
by: Rachel Jeong, et al.
Published: (2020-10-01)

Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation
by: Himanshu V Patel, et al.
Published: (2014-01-01)

Treating a GAD65 antibody-associated limbic encephalitis with Basiliximab, a case study
by: Guido eWidman, et al.
Published: (2015-08-01)

Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome
by: Sailaja Kesiraju, et al.
Published: (2014-01-01)

Correspondence on tea consumption and attenuation of biological aging: author's reply
by: Yi Xiang, et al.
Published: (2024-02-01)

Correspondence (reply): The application conditions of false discovery rate control
by: Hongbin Zhang, et al.
Published: (2023-07-01)

Correspondence: Reply to ‘The experimental requirements for a photon thermal diode’
by: Zhen Chen, et al.
Published: (2017-08-01)

Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report
by: Maiah Zarrabi, et al.
Published: (2023-05-01)

Basiliximab for early perioperative transplant-associated thrombotic microangiopathy after lung transplantation: a case report
by: Naohiro Ijiri, et al.
Published: (2022-09-01)

EXPERIÊNCIA COM USO DE BASILIXIMAB (SIMULECT®) EM UM ÚNICO SERVIÇO DE TRANSPLANTE RENAL
by: Tereza Matuck, et al.
Published: (2005-01-01)

Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
by: Martina Koch, et al.
Published: (2009-01-01)

Comparison of Basiliximab and Anti‐Thymocyte Globulin as Induction Therapy in Pediatric Heart Transplantation: A Survival Analysis
by: David Ansari, et al.
Published: (2016-01-01)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
by: Baigent, C, et al.
Published: (2011)

Efficacy and safety of more intensive lowering of LDL cholesterol Reply
by: Baigent, C, et al.
Published: (2011)

Reply to Fine on Aboutness
by: Yablo, Stephen
Published: (2018)

This side of paradox, or, in defence of the Correspondence Principle: a reply to Herberg and Kemp
by: Neary, J
Published: (1980)

This side of paradox, or, in defence of the Correspondence Principle: a reply to Herberg and Kemp
by: Neary, J
Published: (1980)

This Side of Paradox, or, in Defense of the Correspondence Principle: A Reply to Herberg and Kemp.
by: Neary, J
Published: (1980)